Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
First Claim
Patent Images
1. A composition for the treatment of dry eye and other disorders requiring the wetting of the eye comprising a pharmaceutically acceptable carrier, a pharmaceutically effective amount of one or more HETE derivatives according to formulas (I), (II) or (III), and ethanol in an amount sufficient to enhance the efficacy of the HETE derivative(s):
-
wherein;
X is OR or NHR;
R is H, substituted or unsubstituted alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl, arylalkyl, wherein the substitution is made with a moiety selected from the group consisting of;
alkyl, halogen, hydroxy and functionally modified hydroxy; and
Y is wherein R″
is H or OR″
is a functionally modified hydroxy group.
1 Assignment
0 Petitions
Accused Products
Abstract
Compositions containing one or more HETE derivative(s) and an effective concentration of ethanol and methods of use for treating dry eye are disclosed.
-
Citations
22 Claims
-
1. A composition for the treatment of dry eye and other disorders requiring the wetting of the eye comprising a pharmaceutically acceptable carrier, a pharmaceutically effective amount of one or more HETE derivatives according to formulas (I), (II) or (III), and ethanol in an amount sufficient to enhance the efficacy of the HETE derivative(s):
-
wherein; X is OR or NHR;
R is H, substituted or unsubstituted alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl, arylalkyl, wherein the substitution is made with a moiety selected from the group consisting of;
alkyl, halogen, hydroxy and functionally modified hydroxy; and
Y is wherein R″
is H or OR″
is a functionally modified hydroxy group.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
wherein, X21 and X22 are the same or different and are O, NH(C═
O), O(C═
O), or a direct bond;R22 is H or CH═
CH(CH2)12CH3;
X21—
R1 is OH, or R1 is C12-26 substituted or unsubstituted alkyl or alkenyl;
R2 is C12-26 substituted or unsubstituted alkyl or alkenyl; and
R3 is OH, OCH2CH(NH3+)COO−
, OCH2CH2NH3+, OCH2CH2N+(CH3)3, OCH2CH(OH)CH2OH and O-inositol.
-
-
11. The composition of claim 10, wherein the phospholipid is selected from the group consisting of:
- DPPC, DPPG, DSPI, SPPC, DPPE, DOPS, DSPE, SPPE, DOPE, DPPS, N-stearyl sphingomyelin, N-palmityl sphingomyelin and N-oleyl sphingomyelin.
-
12. The composition of claim 8 wherein the composition comprises an artificial tear component selected from the group consisting of monomeric polyols;
- polymeric polyols;
hyaluronic acid;
chondroitin sulfate;
dextrans;
water-soluble proteins; and
vinyl polymers.
- polymeric polyols;
-
13. The composition of claim 12 wherein the artificial tear component is selected from the group consisting of glycerol;
- propylene glycol;
ethylene glycol;
polyethylene glycol;
hydroxypropylmethyl cellulose;
carboxy methylcellulose sodium;
hydroxy propylcellulose;
hyaluronic acid;
chondroitin sulfate;
dextran 70;
gelatin;
polyvinyl alcohol;
polyvinylpyrrolidone;
povidone;
carbomer 934P;
carbomer 941;
carbomer 940; and
carbomer 974P.
- propylene glycol;
-
14. The composition of claim 1, wherein the composition further comprises one or more ingredients selected from the group consisting of surfactants, tonicity agents, buffers, preservatives, co-solvents and anti-oxidants.
-
15. A method for the treatment of dry eye and other disorders requiring the wetting of the eye comprising administering to a mammal a composition comprising a pharmaceutically effective amount of one or more HETE derivatives according to formulas (I), (II) or (III), and ethanol in an amount sufficient to enhance the efficacy of the HETE derivative(s):
-
wherein; X is OR or NHR;
R is H, substituted or unsubstituted alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl, arylalkyl, wherein the substitution is made with a moiety selected from the group consisting of;
alkyl, halogen, hydroxy and functionally modified hydroxy; and
Y is wherein R″
is H or OR″
is a functionally modified hydroxy group.- View Dependent Claims (16, 17, 18, 19, 20, 21, 22)
-
Specification